0001127602-24-005191.txt : 20240215
0001127602-24-005191.hdr.sgml : 20240215
20240215160131
ACCESSION NUMBER: 0001127602-24-005191
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davis Robert M
CENTRAL INDEX KEY: 0001363076
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-06571
FILM NUMBER: 24643689
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Merck & Co., Inc.
CENTRAL INDEX KEY: 0000310158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 221918501
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
BUSINESS PHONE: 908-740-4000
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL ROAD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
FORMER COMPANY:
FORMER CONFORMED NAME: Merck & Co. Inc.
DATE OF NAME CHANGE: 20091103
FORMER COMPANY:
FORMER CONFORMED NAME: SCHERING PLOUGH CORP
DATE OF NAME CHANGE: 19920703
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-02-13
0000310158
Merck & Co., Inc.
MRK
0001363076
Davis Robert M
MERCK & CO., INC.
126 EAST LINCOLN AVENUE
RAHWAY
NJ
07065
1
1
Chairman, CEO & President
0
Common Stock
2024-02-13
4
M
0
41509
75.36
A
389835.757
D
Common Stock
2024-02-13
4
M
0
108491
73.73
A
498326.757
D
Common Stock
2024-02-13
4
S
0
124676
125.7431
D
373650.757
D
Common Stock
2024-02-13
4
S
0
25324
126.3733
D
348326.757
D
Common Stock
2024-02-14
4
M
0
85021
73.73
A
433347.757
D
Common Stock
2024-02-14
4
S
0
85021
125.3993
D
348326.757
D
Stock Option (Right to Buy)
75.36
2024-02-13
4
M
0
41509
0
D
2021-05-01
2030-04-30
Common Stock
41509
83020
D
Stock Option (Right to Buy)
73.73
2024-02-13
4
M
0
108491
0
D
2022-05-04
2031-05-03
Common Stock
108491
181781
D
Stock Option (Right to Buy)
73.73
2024-02-14
4
M
0
85021
0
D
2022-05-04
2031-05-03
Common Stock
85021
96760
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.2700 to $126.2600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.2650 to $126.525, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.0900 to $125.8200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.
/s/ Kelly E. W. Grez as Attorney-in-Fact for Robert M. Davis
2024-02-15